Genomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 Shares

Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $31.47, for a total value of $157,350.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, October 10th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $31.93, for a total value of $159,650.00.
  • On Tuesday, September 12th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $31.86, for a total value of $159,300.00.

Genomic Health, Inc. (NASDAQ:GHDX) traded down $0.51 during trading on Thursday, reaching $29.98. The company’s stock had a trading volume of 201,753 shares, compared to its average volume of 118,292. Genomic Health, Inc. has a one year low of $26.37 and a one year high of $34.02.

WARNING: “Genomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 Shares” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/11/09/genomic-health-inc-ghdx-coo-g-bradley-cole-sells-5000-shares.html.

Several brokerages recently commented on GHDX. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 price target on shares of Genomic Health in a research note on Wednesday, September 27th. BidaskClub lowered Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Piper Jaffray Companies reissued a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $32.00.

A number of institutional investors have recently bought and sold shares of GHDX. Bank of New York Mellon Corp boosted its stake in Genomic Health by 0.6% in the first quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock worth $2,789,000 after purchasing an additional 500 shares in the last quarter. American International Group Inc. raised its position in shares of Genomic Health by 7.1% during the first quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock worth $362,000 after acquiring an additional 765 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Genomic Health by 5.6% during the first quarter. TIAA CREF Investment Management LLC now owns 71,233 shares of the medical research company’s stock worth $2,243,000 after acquiring an additional 3,808 shares during the last quarter. Legal & General Group Plc raised its position in shares of Genomic Health by 48.7% during the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock worth $196,000 after acquiring an additional 2,038 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Genomic Health by 8.8% during the first quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock worth $49,256,000 after acquiring an additional 126,807 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply